Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07657247

Clinical Evaluation of the Efficacy of a Nasal Spray in the Treatment of Nasal Dryness

The purpose of this study is to see whether the nasal spray can help improve hydration of the nasal mucosa, reduce discomfort linked to nasal dryness, and confirm its safety in patients suffering from nasal dryness.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Nasal Dryness

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gender: female and/or male.
  • Age: adults and children from 6 years old:
  • The physician's score for at least two symptoms, in addition to a dry nose, must average at least 2 at the enrolment visit (Day 0), for a minimum total score of 6.
  • Subjects agree to refrain from taking any medication and/or taking any action to relieve nasal symptoms throughout the study, from Day -4 to Day 7, apart from acetaminophen.
  • Autonomous adult, or minor with the consent of their legal representative.
  • Subject and/or Parent/legal guardian of the subject has given freely and expressly her/his informed consent.
  • Subject and/or Parent/legal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected.
  • Ability of the patient (for adults) or their legal representative (for children) to follow the instructions for product use.
  • Having signed a free and informed consent to participate in the study expressed by the patient (for adults) or by their legal representative (for children) after being informed by the doctor.

Exclusion criteria

  • Subjects taking anticoagulants, antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs), or topical or systemic decongestants within two weeks prior to Visit 1 and during the study.
  • Subjects using other nasal sprays, nasal pumps, nasal irrigation/rinsing devices, or oils, creams, or gels in the nose within two weeks prior to Visit 1 and during the study.
  • Subjects with a history of sensitivity to products related to the product being evaluated.
  • Subjects with any clinically significant comorbid condition that, in the opinion of the principal investigator, could affect the subject's safety and/or participation in the study.
  • Person whose ability to use the product daily and complete the daily follow-up diary is in doubt.
  • Person refusing to sign the informed consent form prior to the study.
  • Person participating or having participated in any other clinical study within the 30 days preceding the study.
  • Person participating in any other clinical study.

Treatment and study plan

Spray pompe nasal

Device

Dosage: 2 sprays per nostril

Primary outcomes

  1. Improvement of the nasal dryness symptoms

    Time frame: Day 0 - Day 0 immediately after first use - Day 7

    The changes between the baseline and day 7 will be assessed using the Rhinitis Sicca Symptom Score (RSSS). The RSSS is constituted by the sum of the following individual symptoms: sensation of dry nose, impairment of nasal breathing/nasal obstruction, crusting, itching/sneezing attacks, pain in the nose, anterior nasal discharge /runny nose, thick nasal discharge, desire to clear one's throat/ dry throat, impairment of smell and impairment of sleep. Patients assessed with each of these symptoms on an ordinal scale of 0-4 (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 = very strong).

Secondary outcomes

  1. Improvement of the total perceive Nasal symptom relief

    Time frame: Day 0 - Day 0 immediately after first use - Day 7

    The changes between the baseline and day 7 in the rhinoscopy score will be assessed. The rhinoscopy score is constituted by the sum of the following symptom: dryness, atrophy, redness, oedema of the nasal mucosa and crusting. The clinician will assess each symptom on an ordinal scale of 0-4 (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 = very strong).

  2. Incidence of Adverse Events

    Time frame: through study completion, an average of 7 days

    Adverse events, if any, will be tabulated by the investigator

Sponsors and collaborators

Lead sponsor

YSLab

Industry

Collaborators

  • Eurofins

Registry information

Official study title

Clinical Evaluation of the Efficacy of a Nasal Spray Based on Isotonic Seawater and Hyaluronic Acid in the Treatment of Nasal Dryness

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 18, 2026
Registry last updated
Jun 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.